三鑫醫療(300453.SZ)子公司獲“一次性使用靜脈輸液針”醫療器械註冊證
格隆匯12月5日丨三鑫醫療(300453.SZ)公佈,公司全資子公司雲南三鑫醫療科技有限公司(“雲南三鑫”)於近日取得國家藥品監督管理局(“國家藥監局”)頒發的《醫療器械註冊證》,產品名稱為一次性使用靜脈輸液針。
“一次性使用靜脈輸液針”用於對人體進行靜脈穿刺輸注藥液或血液用。本產品是臨牀普遍使用的醫療器械,國內本產品生產企業眾多,行業競爭較為充分。
雲南三鑫獲得“一次性使用靜脈輸液針”醫療器械註冊證,進一步豐富了雲南三鑫的產品種類,有利於雲南三鑫快速開拓市場、提升競爭力,對雲南三鑫及公司的發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.